Track topics on Twitter Track topics that are important to you
Precision BioSciences (NASDAQ:DTIL) has announced it has dosed the first patient in its Phase 1/2 a clinical trial of PBCAR0191, which is the company’s first gene-edited allogenic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate. As quoted in the press release: Precision is developing PBCAR0191 in collaboration with Servier, an international pharmaceutical company. PBCAR0191 is … Continued
The post Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial appeared first on Investing News Network.NEXT ARTICLE
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...